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Signaling by EphrinB1 and Eph Kinases in Platelets Promotes Rap1 Activation,
Platelet Adhesion, and Aggregation via Effector Pathways that Do Not Require
Phosphorylation of EphrinB1
Abstract
We have previously shown that platelets express 2 receptor tyrosine kinases, EphA4 and EphB1, and the
Eph kinase ligand, ephrinB1m and proposed that transcellular Eph/ephrin interactions made possible by
the onset of platelet aggregation promote the further growth and stability of the hemostatic plug. The
present study examines how this might occur. The results show that clustering of either ephrinB1 or
EphA4 causes platelets to adhere to immobilized firinogen via αIIbβ3. Adhesion occurs more slowly than
with adenosine diphosphate (ADP) abd requires phosphatidylinositol 3 (PI3)—kinase and protein kinase C
activity but not ephrinB1 phosphorylation. By itself, Eph and ephrin signaling is insufficient to cause
aggregation or the binding of soluble fibrinogen, but it can potentiate aggregation initiated by a Ca++
ionophore or by agonists for thrombin and thromboxane receptors. It also enhances Rap1 activation
without requiring ADP secretion, ephrinB1 phosphorylation, or the activation of PI3-kinase and Src. From
this we conclude that (1) Eph/ephrin signaling enhances the ability of platelet agonists to cause
aggregation provided that those agonists can increase cytosolic Ca++; (2) this is accomplished in part by
activating Rap1; and (3) these effects require not phosphotyrosine-based interactions with the ephrinB1
cytoplasmic domain.
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HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY

Signaling by ephrinB1 and Eph kinases in platelets promotes Rap1 activation,
platelet adhesion, and aggregation via effector pathways that do not require
phosphorylation of ephrinB1
Nicolas Prévost, Donna S. Woulfe, Massimiliano Tognolini, Takako Tanaka, Wenying Jian, Ryan R. Fortna,
Hong Jiang, and Lawrence F. Brass

We have previously shown that platelets
express 2 receptor tyrosine kinases,
EphA4 and EphB1, and the Eph kinase
ligand, ephrinB1, and proposed that transcellular Eph/ephrin interactions made possible by the onset of platelet aggregation
promote the further growth and stability
of the hemostatic plug. The present study
examines how this might occur. The results show that clustering of either ephrinB1 or EphA4 causes platelets to adhere to immobilized fibrinogen via ␣IIb␤3.
Adhesion occurs more slowly than with

adenosine diphosphate (ADP) and requires phosphatidylinositol 3 (PI3)–kinase and protein kinase C activity but not
ephrinB1 phosphorylation. By itself, Eph
and ephrin signaling is insufficient to
cause aggregation or the binding of
soluble fibrinogen, but it can potentiate
aggregation initiated by a Caⴙⴙ ionophore or by agonists for thrombin and
thromboxane receptors. It also enhances
Rap1 activation without requiring ADP
secretion, ephrinB1 phosphorylation, or
the activation of PI3-kinase and Src. From

this we conclude that (1) Eph/ephrin signaling enhances the ability of platelet
agonists to cause aggregation provided
that those agonists can increase cytosolic Caⴙⴙ; (2) this is accomplished in part
by activating Rap1; and (3) these effects
require oligomerization of ephrinB1 but
not phosphotyrosine-based interactions
with the ephrinB1 cytoplasmic domain.
(Blood. 2004;103:1348-1355)

© 2004 by The American Society of Hematology

Introduction
Formation of a platelet plug at sites of vascular injury begins with
the arrest of circulating platelets on collagen and continues as
additional platelets are recruited by secreted or locally generated
agonists such as adenosine diphosphate (ADP), thromboxane A2
(TxA2), and thrombin. Once initiated, the ability of the platelet
mass to continue to grow depends in part upon the intracellular
events that promote the binding of the integrin ␣IIb␤3 on the platelet
surface to fibrinogen, fibrin, and von Willebrand factor (VWF). In
turn, sustained contacts between platelets, which can only occur
once aggregation has begun, make possible a wave of contactdependent signaling that favors the further growth and stability of
the platelet plug. In this context, the phrase “contact-dependent
signaling” refers to the intracellular signaling events initiated by
the binding of proteins on the surface of one platelet to proteins on
the surface of an adjacent platelet, either directly or indirectly.
Among the examples of contact-dependent signaling that have
been described in platelets, outside-in signaling through ␣IIb␤3 is
the best known; however, others exist as well. We have recently
shown that human platelets express on their surface 2 Eph kinases,
EphA4 and EphB1, as well as the Eph kinase ligand, ephrinB1.1
Eph kinases are receptor tyrosine kinases with an extracellular
ligand-binding domain and an intracellular kinase domain. Eph
kinases and their ligands, which are known as ephrins, play a role in
axon guidance2 and development of the vascular system.3,4 Ephrins
fall into A and B groups based on their membrane anchor. Ephrin A
family members have a glycosylphosphatidylinositol (GPI) anchor.

Ephrin B family members have a transmembrane domain and a
cytoplasmic domain. The cytoplasmic domain includes sites for
tyrosine phosphorylation and a C-terminal binding site for cytosolic proteins with PDZ domains. This gives the B ephrins at least 2
ways to engage in protein/protein interactions, both of which allow
the ligand to serve as a “receptor” even though it does not have a
kinase domain.5,6 Eph kinases are also divided into A and B
families based on their ephrin-binding preferences, although EphA4
in particular can bind to ephrin B as well as ephrin A family
members.7 Thus, human platelets express on their surface at least 2
Eph kinases and a ligand that can bind to either.
Studies in cells that are normally adherent have shown that
transcellular interactions between ephrins and Eph kinases can
produce signals in both the ephrin- and the Eph kinase–presenting
cell and that these signals can result in increased adhesion or
repulsion.2,8,9 Given the fact that platelets are normally mobile, we
have previously proposed that Eph/ephrin interactions promote the
growth and stability of the platelet plug.10 Such interactions would
not be expected to occur during the transient contacts between
circulating platelets but would be made possible by the onset of
aggregation. In support of this hypothesis, we observed that
signaling through EphA4 and ephrinB1 causes platelets to adhere
to immobilized fibrinogen and triggers the tyrosine phosphorylation of the ␤3 cytoplasmic domain of ␣IIb␤3. We also observed that
EphA4 forms a complex with Fyn, Lyn, and the cell adhesion
molecule L1 during platelet aggregation, and that blockade of
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Eph/ephrin interactions prevents this association. Finally, we found
that blockade of Eph/ephrin interactions during platelet aggregation initiated by ADP, a protease-activated receptor 1 (PAR1)
agonist (SFLLRN), or collagen causes premature disaggregation
and inhibits clot retraction.1,11,12
The goal of the present study was to better understand the ways
in which Eph/ephrin signaling can regulate ␣IIb␤3 activation in
platelets and identify mechanisms that might be involved. We now
show that Eph/ephrin signaling is able to potentiate platelet
aggregation in response to agonists and also promotes the ability of
platelet agonists to activate Rap1, a Ras family member that has
been linked to integrin activation in a variety of cell types including
platelets. We also show that the adhesion of platelets to immobilized fibrinogen in response to Eph/ephrin interactions requires
phosphatidylinositol 3 (PI3)–kinase and protein kinase C, but,
interestingly in light of what is known about signaling by ephrin B
family members, neither the induction of adhesion nor Rap1
activation requires ephrin B1 phosphorylation or the activation of
Src kinases. These results help to establish a model in which
contact-dependent Eph/ephrin interactions between adjacent platelets promote platelet aggregation by helping to sustain integrin
activation.

Materials and methods
Chemicals and reagents
Alexa-Fluor 594–conjugated fibrinogen was from Molecular Probes (Eugene, OR). Wortmannin, LY294002, PP2, PP3, ionomycin, U46619, and
bis-indolylmaleimide were from Calbiochem (San Diego, CA). ADP,
apyrase, RGDS peptide, phorbol myristate acetate (PMA), and the protease
inhibitor cocktail 4-(2-aminoethyl) benzenesulfonyl fluoride, pepstatin A,
trans-epoxysuccinyl-L-Leucyl-amido (4-guanidino) butane (E-64), bestatin,
leupeptin, and aprotinin were purchased from Sigma (St Louis, MO).
Protein A and G agarose were obtained from Gibco BRL (Gaithersburg,
MD). Cyanogen bromide (CNBr)–activated Sepharose 4 was from Amersham Pharmacia Biotech (Piscataway, NJ). Convulxin was a gift from Dr
Mark Kahn (University of Pennsylvania, Philadelphia, PA).
Platelet preparation
Blood was obtained from healthy volunteer donors, who had not taken
medications for at least 10 days, and was anticoagulated 1:5 with ACD
(trisodium citrate 65 mM, citric acid 70 mM, dextrose 100 mM, pH 4.4).
Platelet-rich plasma (PRP) was obtained by centrifugation at 100g for 20
minutes and then recentrifuged at 220g for 15 minutes after adding 1 M
prostaglandin I2 (PGI2). The platelet pellet was resuspended in NaCl 150
mM, Na2EDTA (Na2 ethylenediaminetetraacetic acid) 1 mM, HEPES
(N-2-hydroxyethylpiperazine-N⬘-2-ethanesulfonic acid) 10 mM, pH 6.5,
with 1 M PGI2 and then centrifuged for 15 minutes at 220g. After
washing, the platelets were resuspended in modified Tyrode buffer (NaCl
137 mM, HEPES 20 mM, glucose 5.6 mM, bovine serum albumin [BSA]
1g/L, MgCl2 1 mM, KCl 2.7 mM, NaH2PO4 3.3 mM, pH 7.4) and adjusted
to a final platelet count of 1000 ⫻ 109/L. Gel-filtered platelets (GFPs) were

Figure 1. Activation of ephrinB1 or EphA4 causes
platelet adhesion to fibrinogen. Adhesion was measured using a colorimetric assay as described in “Materials and methods.” (A) Platelets were incubated with ADP
(20 M) or without an agonist for the times indicated. The
figure is representative of 3 experiments. (B-C) Platelets
were stimulated with ADP (20 M), GST-EphB1 (5
g/mL; panel B), or GST-ephrinA4 (5 g/mL; panel C) for
the times indicated. The results are the mean ⫾ SEM for
4 experiments expressed as the “adhesion index,” which
is defined in “Materials and methods.”
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prepared by passing the platelet-rich plasma through columns of Sepharose
2B (Pharmacia, Uppsala, Sweden) using modified Tyrode buffer for elution.
Antibodies
Antibodies for EphA4, ephrinB1, and phosphotyrosine (PY20) were
purchased from Santa Cruz (Santa Cruz, CA). The antibody used to
precipitate EphA4 was produced in chickens immunized with a peptide
corresponding to residues M976-V986 of human EphA4. The antibody
used to precipitate ephrinB1 was purchased from R&D Systems (Minneapolis, MN). Antiphosphotyrosine antibody 4G10 was from Upstate Biotechnology (Lake Placid, NY). The Rap1 antibody was from Transduction Labs
(Lexington, KY).
Platelet adhesion
Platelet adhesion was measured using a modification of the method
described by Bellavite et al.13 Microtiter plates were coated overnight at
4°C with either 2 mg/mL fibrinogen or 4 mg/mL BSA in phosphate-buffered
saline (PBS) and then blocked with 5 mg/mL BSA for 15 to 30 minutes.
Gel-filtered platelets (50 L of 100 ⫻ 109/L) were added to each well and
preincubated at 37°C for 5 minutes before the addition of an agonist in 25
L of Tyrode buffer with 3 mM CaCl2. After incubation at room
temperature, the plates were washed 4 times in PBS to remove loosely
adherent and nonadherent platelets, and acid phosphatase substrate (150 L
of 5 mM P-Nitrophenyl phosphate in 0.1 M citrate/0.1% Triton X-100) was
added to each well. This reaction was allowed to proceed for 1 hour at room
temperature in the dark and then stopped with 100 L of 2N NaOH per well
and optical density (OD) 405 was measured. To determine the fraction of
applied platelets that became adherent, an aliquot of platelet suspension
containing the same total number of platelets was separately lysed and
assayed for acid phosphatase activity. Except for Figure 1A, the results of
each experiment were expressed as the “adhesion index” that was defined as
the average OD 405 in the presence of an agonist at any given time divided
by the average OD 405 in the absence of an agonist at time zero.
Fibrinogen binding
Platelets (300 L of gel-filtered platelets in buffer supplemented with 1 mM
CaCl2) were incubated with 100 g/mL Alexa-Fluor 594–labeled fibrinogen for 30 minutes in the dark at room temperature in presence of the
appropriate agonist. Platelets were then fixed for 10 minutes at room
temperature by adding an equal volume of 2% formaldehyde–Tyrode
buffer, sedimented at 1310g for 20 seconds, resuspended in 0.5 mL
phosphate buffered saline, and analyzed by flow cytometry.
Platelet aggregation
Platelet aggregation was observed in a ChronoLog platelet aggregometer
(Havertown, PA) using gel-filtered platelets (200 ⫻ 109/L) supplemented
with 1 mM CaCl2 and 300 g/mL fibrinogen.
Rap1 activation
Washed platelets (400 ⫻ 109/L) in Tyrode buffer with 1 mM CaCl2 were
stimulated with an agonist or inhibitor as indicated, lysed with 2 ⫻ buffer
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(20% glycerol, 2% nonidet P-40 [NP-40], 100 mM Tris-HCl, pH 7.4, 400
mM NaCl, 5 mM MgCl2, with mammalian protease inhibitor cocktail), and
then incubated for 2 hours with glutathione S-transferase (GST)–RalGDSRBD (a fusion of GST with the Ral binding domain [RBD] from the protein
RalGDS; 30 g/mL) and 50 L glutathione-Sepharose at 4°C while
rotating. The beads were then washed once with 1 ⫻ lysis buffer followed
by 3 washes with PBS. Guanosine 5⬘-triphosphate (GTP)–bound Rap1 was
eluted with sodium dodecyl sulfate (SDS) sample buffer, separated by 10%
SDS–polyacrylamide gel electrophoresis (SDS-PAGE), and immunoblotted
with anti-Rap1 antibody (1:500).
Immunoprecipitation and Western blotting
Platelets were either lysed in RIPA buffer (Triton X-100 1%, deoxycholate
1%, SDS 0.1%, 158 mM NaCl, Tris 10 mM pH 7.2, NaEDTA 5 mM) or in
NP-40 buffer (1% NP-40, 50 mM Tris, 150 mM NaCl), in the presence of
protease inhibitors and NaVO4 (1 mM). Insoluble materials were removed
by centrifugation at 16 000g for 15 minutes at 4°C. The resulting
supernatants were precleared with protein A agarose (for rabbit antibodies),
protein G agarose (for mouse antibodies), or Sepharose 4B beads (for
chicken anti-EphA4) and then incubated with the precipitating antibody
overnight at 4°C with rocking. Protein/antibody complexes were isolated by
incubation with either protein A agarose, protein G agarose, or Sepharose
4B for 1 hour at 4°C with rocking. After 3 washes in PBS, the beads were
boiled in sample buffer (2% SDS, 1% ␤-mercaptoethanol, 0.008% bromophenol blue [BPB], 80 mM Tris pH 6.8, 1 mM EDTA). The samples were
then analyzed by SDS-PAGE and transferred to nitrocellulose membranes.
After the transfer, the membranes were blocked in 5% BSA for a
phosphotyrosine blot or in 5% milk for any other Western blot. When
indicated, the membranes were stripped in 62.5 mM Tris-HCl, pH 6.8, with
2% SDS and 100 mM ␤-mercaptoethanol for 10 minutes at 63°C and then
reprobed with a different primary antibody.
Fusion proteins
The EphA4 exodomain (W54 to V430) was subcloned by polymerase
chain reaction (PCR) using a forward primer containing a custom EcoRI
site, 5⬘AATGAATTCAACTGAT TGGTCTGGGTTAGG3⬘, and a reverse
primer containing a custom BamHI site, 5⬘TCCGGATCCTGGGAGGAAGTGAGTATCATGGATG3⬘. The fragment was subcloned in the
pGEX1T vector (Amersham Pharmacia BioTech). The resulting construct was transformed into the Escherichia coli strain BL21 DE3.
Recombinant GST-EphA4 was purified using the Pharmacia GST
purification kit. The presence of oligomers was confirmed by electrophoresis under nondenaturing conditions. Monomeric His6-tagged proteins corresponding to the exodomains of EphB1 and ephrinA4 (HisEphB1 and His-ephrinA4), GST-EphB1, GST-ephrinA4, and GST⌬EphB1 were prepared as previously described.1

Results
We have previously observed with fluorescence microscopy that
activation of EphA4 or ephrinB1 causes platelets to adhere and
spread on immobilized fibrinogen.1 In the present studies,
adhesion was quantitated using a microtiter plate assay. To
minimize agonist-independent binding of the platelets, measurements were performed at room temperature and the fibrinogencoated microtiter plate wells were blocked with bovine albumin
(BSA). After washing to remove nonattached cells, the adherent
platelets were detected using a chromogenic substrate for acid
phosphatase. Under these conditions, there was little “background” adhesion in the absence of an agonist at times as long as
60 minutes but a prompt increase in adhesion in response to
ADP (Figure 1A). In order to normalize values, results from
replicate experiments were combined using a calculated “adhesion index” (defined in “Platelet adhesion”). Approximately half
of the applied platelets typically became adherent upon stimulation with ADP. Isolated signaling through ephrinB1 or EphA4
was triggered by incubating the platelets with oligomeric
proteins composed of the exodomain of either EphB1 (to
activate ephrinB1) or ephrinA4 (to activate EphA4) fused to
glutathione-S-transferase (GST).
Consistent with our previous observations, adhesion occurred following the addition of either GST-EphB1 or GSTephrinA4. There was little or no adhesion when fibrinogen was
omitted or when the platelets were stimulated with either GST
alone or with a variant protein (denoted GST-⌬EphB1) lacking
residues needed for binding to ephrinB114 (Figures 1B-C and
2A-C). His-tagged monomeric exodomains of EphB1 or ephrinA4 were unable to cause adhesion. Preincubating platelets
with the monomers prevented a subsequent response to GSTEphB1 or GST-ephrinA4 (Figure 2A-B) but had no effect on
adhesion in response to the PAR1 agonist peptide, SFLLRN (not
shown). The extent of adhesion in response to clustering EphA4
or ephrinB1 approached that seen with ADP, but the rate was
slower (Figure 1B-C). Addition of the integrin-blocking peptide,
RGDS, or an anti-␣IIb␤3 antibody (A2A9) prevented adhesion
(Figure 2D-F). Taken together, these results show that isolated
signaling produced by oligomerization of EphA4 or ephrinB1
causes a gradual sustained increase in ␣IIb␤3-dependent attachment of platelets to immobilized fibrinogen.

Figure 2. Platelet adhesion to fibrinogen in response
to ephrinB1 or EphA4 is mediated by ␣IIb␤3.
(A-B) Platelets were preincubated for 30 minutes with
recombinant monomeric proteins corresponding to the
exodomain of either (A) EphB1 (10 g/mL) or (B) ephrinA4 (10 g/mL) and then stimulated with GST-EphB1,
GST-ephrinA4, or GST for an additional 20 minutes.
Mean ⫾ SEM for 3 experiments. (C) Platelets were
incubated with GST-EphB1 or GST-⌬EphB1 for 20 minutes. Mean ⫾ SEM for 6 experiments. (D-F) Platelets
were preincubated for 30 minutes with the monoclonal
anti-␣IIb␤3, A2A9, or with RGDS, and then stimulated with
GST-EphB1 or GST-ephrinA4 for 20 minutes as indicated. Mean ⫾ SEM for 3 to 4 experiments.
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Figure 3. Activation of ephrinB1 potentiates platelet
aggregation. (A) Gel-filtered platelets (200 ⫻ 109/L) were
incubated with either 2 g/mL GST-EphB1, GST⌬EphB1, GST-ephrinA4, or 20 M ADP in presence of
100 g/mL Alexa-Fluor 594–labeled fibrinogen as described in “Materials and methods.” The results shown
are representative of 3 experiments. (B-D) Gel-filtered
platelets (200 ⫻ 109/L to 400 ⫻ 109/L) were stimulated
as indicated with U46619, SFFLRN, or ionomycin in the
presence of GST-EphB1, GST-⌬EphB1, or buffer, in the
order shown. Representative of 4 experiments.

EphrinB1 signaling potentiates platelet aggregation

We next asked whether signaling through ephrinB1 or EphA4 is
able to evoke the high-affinity state of ␣IIb␤3 needed for soluble
fibrinogen to bind and platelet aggregation to occur. In the
experiment shown in Figure 3A, platelets were incubated with
GST-EphB1, GST-ephrinA4, or ADP, and labeled fibrinogen binding was measured by flow cytometry. Under these conditions ADP
caused fibrinogen binding but the GST fusion proteins did not.
When added by itself, GST-EphB1 also failed to cause platelet
aggregation (Figure 3 and data not shown). However, incubation
with GST-EphB1 increased the rate and extent of aggregation
initiated by SFLLRN or the TxA2 analog, U46619 (Figure 3B-C).
GST-EphB1 also increased the ability of the Ca⫹⫹ ionophore,
ionomycin, to cause aggregation (Figure 3D). It did not increase
platelet responses to epinephrine (not shown).
Therefore, although ephrinB1 signaling alone is unable to cause
the binding of soluble fibrinogen to ␣IIb␤3 and platelet aggregation,
it can potentiate the ability of platelet agonists to do so. Notably,
each of the agonists that were tested (SFLLRN, U46619, and
ionomycin) cause an increase in cytosolic Ca⫹⫹, which does not
occur with GST-EphB1. This suggests that the inability of isolated
Eph/ephrin signaling to activate ␣IIb␤3 is due in part to the failure of
such signaling to mobilize Ca⫹⫹.

Rap1 and might, therefore, explain the observed enhancement of
aggregation, platelets were incubated with the TxA2 analog,
U46619, in the presence or absence of GST-EphB1. Rap1 activation was detected using a pull-down assay with a binding protein
specific for the GTP-bound form of Rap1, which was then detected
by immunoblotting with a Rap1 antibody. U46619 by itself caused
Rap1 activation. Addition of GST-EphB1 caused a further increase
in Rap1 activation (Figure 4A). GST-EphB1 also enhanced the
ability of ionomycin to activate Rap1.
To understand how ephrinB1 activation might lead to Rap1
activation, platelets were preincubated with either apyrase,
LY294002, or PP2 to, respectively, hydrolyze secreted ADP and
inhibit PI3-kinases or Src family members. Afterward, the platelets
were incubated with GST-EphB1, and Rap1 activation was measured (Figure 4B). Treating platelets with apyrase caused a small

Increased activation of Rap1

Although the mechanisms underlying ␣IIb␤3 activation in platelets
are not fully understood, recent studies suggest that the Ras-related
protein, Rap1, is involved.15-20 Like other Ras family members,
Rap1 is active in the GTP-bound state and inactive when bound to
guanosine 5⬘-diphosphate (GDP). In theory, agonists can cause an
increase in GTP-bound Rap1 either by turning on (or recruiting) a
guanine nucleotide exchange factor (GEF) or by inhibiting a Rap1
GTPase-activating protein (GAP). We have shown previously that
oligomerization of ephrinB1 by EphB1 in platelets activates Rap1
in the absence of an agonist.1 To see whether this response to
ephrinB1 signaling enhances the ability of an agonist to activate

Figure 4. EphrinB1 signaling potentiates Rap1 activation. (A) Gel-filtered
platelets were incubated with the agents indicated, then Rap1-GTP was isolated and
analyzed as described in “Materials and methods.” (B) Washed platelets (500 ⫻
109/L) were preincubated for 15 minutes with apyrase 1 U/mL, LY294002 100 M,
PP2 30 M, or vehicle, then stimulated with agonist for 5 minutes. The results are
from 1 of 2 experiments with identical results.

1352

BLOOD, 15 FEBRUARY 2004 䡠 VOLUME 103, NUMBER 4
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decrease in GTP-bound Rap1 in response to GST-EphB1 (Figure
4B lanes 1-3) but eliminated Rap1 activation by ADP (Figure 4B
lanes 6-7), suggesting that ephrinB1 is able to promote Rap1
activation by a mechanism that is largely independent of secreted
ADP. The Rap1 activation that was observed in the presence of
apyrase (ie, the Rap1 activation that is not secondary to ADP
release) was minimally affected by inhibiting either PI3-kinase or
Src family members (Figure 4B lanes 4-5). Notably, under the same
conditions, inactivation of the Src family members in platelets with
PP2 abolished Rap1 activation by convulxin (Figure 4B lanes 8-9)
showing that GST-EphB1 and convulxin (which binds to glycoprotein VI [GP VI]) employ different mechanisms for Rap1 activation.
Convulxin signals via the GP VI/Fc␥ complex, which requires
phosphorylation of the Fc␥ chain cytoplasmic domain by a Src
family member in order for events such as phospholipase C␥
activation to occur. Potential mechanisms for Rap1 activation by
ephrinB1 are discussed in “Mechanisms of ephrinB1 signaling.”
Mechanisms of ephrinB1 signaling

Two mechanisms for protein/protein interactions and signaling
have been identified for ephrin B family members: one is mediated
by the PDZ target domain at the distal C-terminus of the ephrin, the
other depends on the phosphorylation of tyrosine residues within
the cytosolic domain of the ephrin by Src family members.5,6 In
view of the fact that PP2 did not inhibit Rap1 activation by
ephrinB1, we asked whether ephrinB1 can become phosphorylated
in platelets. In Figure 5A-B, platelets were incubated with GSTEphB1, GST-⌬EphB1, or monomeric EphB1 exodomains (denoted
His-EphB1 in Figure 5). Afterward, ephrinB1 was precipitated and
blotted for phosphotyrosine. The results show that ephrinB1 is not
phosphorylated in resting platelets but becomes phosphorylated
when platelets are incubated with GST-EphB1. On the other hand,
neither GST-⌬EphB1 nor the monomeric EphB1 exodomains
cause ephrinB1 phosphorylation. The time course of phosphorylation in response to GST-EphB1 is similar to the time course for
platelet adhesion to fibrinogen (compare Figures 1B and 5B).
Similarly, addition of GST-ephrinA4 to platelets caused phosphorylation of EphA4 (Figure 5C).
Although these data show that ephrinB1 can become phosphorylated in platelets, they do not establish that phosphorylation is
required for ephrinB1-initiated responses and, in fact, this does not
appear to be the case. In the experiments shown in Figure 6,
ephrinB1 phosphorylation and platelet adhesion were measured in
the presence of the Src inhibitor, PP2. PP2 (but not the inactive
congener, PP3) abolished ephrinB1 phosphorylation in response to
GST-EphB1. However, PP2 had no effect on platelet adhesion to
fibrinogen (Figure 6B). An additional control showed that adhesion
in response to convulxin was, as would be expected, abolished by
PP2. As a final step, we measured the phosphotyrosine content of
ephrinB1 immunoprecipitated from platelets that had been allowed
to aggregate in response to PMA, ADP, SFLLRN, convulxin,
U46619, or ionomycin. None of these agonists caused detectable
ephrinB1 phosphorylation (Figure 6C). Therefore, we conclude
that although ephrinB1 can become phosphorylated when directly
stimulated in platelets, phosphorylation is not required for adhesion, nor does it occur at a detectable level during the Eph/ephrin
interactions that accompany agonist-induced platelet aggregation.
If ephrinB1 signaling in platelets does not require phosphorylation of the ephrin, what other mechanisms are involved? To address
that question, GST-EphB1–induced adhesion was measured in the
presence of apyrase, the protein kinase C inhibitor, bis-indolylmaleimide, and the PI3-kinase inhibitors, wortmannin and LY294002.

Figure 5. Phosphorylation of ephrinB1 and EphA4 in platelets. (A) Platelets were
incubated with GST-EphB1 (5 g/mL), GST-⌬EphB1 (5 g/mL), or monomeric
His-EphB1 (10 g/mL) for 30 minutes and then lysed. EphrinB1 was immunoprecipitated (IP) and then immunoblotted (IB) with the antiphosphotyrosine antibodies PY20
and 4G10. Afterward, the blots were reprobed with anti-ephrinB1. The results shown
are representative of 2 experiments. (B) Platelets were incubated with GST-EphB1 (5
g/mL) for the times indicated. EphrinB1 was immunoprecipitated and then immunoblotted as indicated. (C) Platelets were incubated with GST-ephrinA4 for the times
indicated and then lysed. EphA4 was immunoprecipitated and then immunoblotted
as indicated. The results are representative of 3 experiments.

The results are shown in Figure 7. Apyrase blocked the effects of
exogenous ADP but had no significant effect on adhesion in
response to GST-EphB1. In contrast, inhibition of protein kinase C
with bis-indolylmaleimide blocked adhesion. Adhesion was also
inhibited by wortmannin and LY294002, although notably inhibition of PI3-kinase did not prevent Rap1 activation (Figure 4).
Taken together, these results suggest that PI3-kinase plays a role in
ephrinB1-dependent adhesion, but this role is either downstream of
Rap1 activation or on a separate pathway.

Discussion
The initial stages of platelet activation in vivo are heavily
dependent on signaling through G protein–coupled receptors or the
GP VI complex, leading to the activation of phospholipase C ␤ and
␥ isoforms and, eventually, activation of ␣IIb␤3. Although this is
sufficient to initiate platelet aggregation, additional signaling
events appear to have a role in the continued growth and stability of
the hemostatic plug. These events are dependent upon or facilitated
by platelet-platelet contacts that can only occur once platelet
aggregation has begun. Outside-in signaling through integrins
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Figure 6. Phosphorylation of ephrinB1 during adhesion and aggregation.
(A) Platelets were preincubated with 10 M PP2, 10 M PP3, or vehicle for 10
minutes at room temperature and then activated with GST-EphB1 (3 g/mL) for 30
minutes. EphrinB1 was immunoprecipitated and then immunoblotted with the
antiphosphotyrosine antibodies PY20 and 4G10 or with anti-ephrinB1. The results
shown are representative of 2 experiments. (B) Platelets were preincubated for 15
minutes with either PP2 or PP3 and then stimulated for 20 minutes with GST-EphB1
or GST-ephrinA4 in fibrinogen-coated wells. The results shown are the mean ⫾ SEM
for 4 experiments. (C) Platelets were incubated with an agonist for 5 minutes under
conditions allowing aggregation to occur or with GST-EphB1 for 30 minutes as a
control, after which ephrinB1 was immunoprecipitated and then immunoblotted with
either PY20 and 4G10 or with anti-ephrinB1. Final concentrations: PMA 100 nM, ADP
20 M, SFLLRN 50 M, convulxin 1 M, U46619 5 M, ionomycin 5 M, and
GST-EphB1 5 g/mL. The results shown are representative of 3 experiments. The
same results were obtained when the incubation with the agonists was extended to
30 minutes.

represents one example of contact-dependent signaling. Thus,
platelets from mice in which outside-in signaling through ␣IIb␤3
has been impaired by mutating Y747 and Y759 in the cytoplasmic
domain of ␤3 have a phenotype that includes impaired aggregation
and defective clot retraction.21,22
We have proposed previously that Eph/ephrin interactions
provide an additional source of contact-dependent signaling during
human platelet plug formation. In support of this hypothesis, we
have shown elsewhere that forced clustering of EphA4 and
ephrinB1 causes platelets to adhere and spread on immobilized
fibrinogen, and that blockade of Eph/ephrin interactions inhibits
platelet aggregation.1,11,12 In this study, we investigated how
Eph-ephrin signaling might contribute to platelet adhesion and
aggregation. We were particularly interested in understanding how
ephrinB1 might contribute to platelet activation since ephrinB1,
like other ephrin B family members, lacks intrinsic kinase activity
and can serve solely as a means to oligomerize (and activate) Eph
kinases or can generate signals itself. The results show that at least
2 separate mechanisms appear to be at work.
Stated succinctly, our results show the following: (1) Isolated
Eph-ephrin signaling is sufficient to initiate platelet adhesion to
fibrinogen but not the binding of soluble fibrinogen or aggregation.
(2) Platelet adhesion to fibrinogen initiated by ephrin signaling is
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blocked by RGDS and A2A9 and is therefore mediated by ␣IIb␤3.
(3) Although insufficient to cause platelet aggregation, Eph/ephrin
signals can enhance aggregation induced by agonists or by a Ca⫹⫹
ionophore and potentiate Rap1 activation. (4) Eph/ephrin–
mediated adhesion occurs slowly in comparison to other agonists
(10-30 minutes), but the ability of Eph/ephrin interactions to
potentiate aggregation is evident immediately. (5) Ephrin-mediated
adhesion is dependent on PI3-kinase and protein kinase C but
activation of Rap1 is not. (6) Both adhesion and Rap1 activation by
ephrinB1 require clustering of the ephrin, but neither requires
tyrosine phosphorylation of ephrinB1 nor the involvement of Src
family kinases.
The involvement of ␣IIb␤3 is not unexpected but revealing,
nonetheless, in light of other observations. Whatever the activation
state of ␣IIb␤3 required for the integrin to bind to immobilized as
opposed to soluble fibrinogen, it is now clear that isolated Eph
kinase and ephrin signaling can achieve the former but not the
latter. The observation that signaling through Eph kinases can
regulate the adhesive function of integrins is consistent with
previous studies.23-26 However, most of those studies were performed using cells that are normally adherent, unlike platelets, and
both increases and decreases in integrin function were observed.
For example, activation of EphB1 causes endothelial cells to attach
25
via ␣v␤23
3 and P19 cells to attach to fibrinogen. On the other hand,
activation of EphB2 on NIH-3T3 or HEK-293T cells inhibits
adhesion,24 and activation of EphA2 in PC-3 cells inhibits both
adhesion and spreading.26 Whether Eph/ephrin signaling causes an
increase or decrease in integrin function presumably depends on
the repertoire of effector molecules expressed in a given cell type.
On platelets, an increase in attachment due to Eph/ephrin signaling
appears to be the rule.
Although signaling through ephrinB1 is insufficient to cause
soluble fibrinogen binding or platelet aggregation, it is clearly able
to potentiate platelet responses to agonists. If Eph/ephrin interactions are to extend and stabilize platelet aggregates after they begin
to form, as we hypothesize, then we might expect that signaling by
Eph kinases and ephrins would be especially important in platelets
that have also been exposed to soluble agonists. Thus, our
observation that ephrin signaling enhances aggregation only in the
presence of other agonists is a finding that supports this hypothesis.
If signaling through ephrinB1 promotes integrin engagement
and supports aggregation in platelets, how does it do so? One
leading possibility is that the potentiation of aggregation is linked
to the activation of Rap1. Several prior observations have suggested that Rap1 activation promotes integrin activation in platelets. For example, Bertoni et al17 have shown that overexpression of
an inactive Rap1 mutant inhibits agonist-induced ␣IIb␤3 activation

Figure 7. Inhibition of GST-ephrinB1-induced platelet adhesion. Platelets were
preincubated for 15 minutes with each inhibitor and then stimulated for 20 minutes
with GST-EphB1 or ADP. The results are the mean ⫾ SEM for 6 experiments.
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PRÉVOST et al

in megakaryocytes. They also found that expression of constitutively active Rap1 was not sufficient by itself to activate ␣IIb␤3 but
potentiated activation of the integrin by an agonist, as does
signaling through ephrinB1. Together with our data showing that
ephrin B1 signaling activates Rap1 and potentiates the ability of
other platelet agonists to do so, this suggests that ephrin signaling
potentiates aggregation by enhancing activation of Rap1.
If isolated ephrinB1 signaling can cause Rap1 activation, why
does it not also cause platelet aggregation? The studies in
megakaryocytes cited above suggest that activated Rap1 by itself is
incapable of activating ␣IIb␤3. However, clustering of ephrinB1 in
platelets enhances aggregation and activation of Rap1 in response
to a Ca⫹⫹ ionophore. Because ephrinB1 signaling by itself does not
cause an increase in the cytosolic Ca⫹⫹ concentration in platelets,1
it appears that the combination of ephrin signaling plus an increase
in cytosolic Ca⫹⫹ provides everything needed for platelets to bind
soluble fibrinogen and aggregate.
Finally, the results of the present studies provide additional
information about the molecular basis for signaling by ephrinB1 in
platelets. Unlike the receptor kinases EphA4 and EphB1, ephrinB1
lacks a kinase domain. However, ephrins also become activated
when they are bound and clustered by their surface ligands.
Clustered ephrins then serve as the nidus for signaling complexes.
Two distinct modes of signaling downstream of ephrin B family
members have been identified: one is dependent on tyrosine
phosphorylation of the cytosolic domain of the ephrin by a Src
family member, followed by the binding of protein(s) with Src
homology 2 (SH2) or phosphotyrosine binding protein (PTB)
domains5,6; the other is dependent on the binding of cytosolic
proteins with PDZ domains.27-30 The present studies show quite
clearly that ephrinB1 phosphorylation is not required in platelets:
complete elimination of phosphorylation had no effect on either
adhesion or Rap1 activation. This novel finding in platelets extends
a very recent report of phosphorylation-independent activation of
c-Jun N-terminal kinase (JNK) by ephrinB1.31
The alternative to phosphotyrosine-based interactions is the
PDZ target domain in ephrinB1. Guanine nucleotide exchange
factors (GEFs) for Ras family members interact with B ephrins by
this mechanism. Whether an appropriate PDZ-containing GEF
exists in platelets and performs this function for Rap1 remains to be
established. However, a direct link of this sort would be expected to
be phosphorylation independent and thus not inhibited by PP2, as
we have shown for ephrinB1-induced Rap1 activation. Such a link

Figure 8. Eph/ephrin signaling in platelets promotes integrin engagement.
EphrinB1 on the surface of platelet can serve as both a ligand for Eph kinases on
adjacent platelets and as the focus for a signaling complex that promotes Rap1
activation and integrin engagement in response to agonists.

would also be expected to be independent of PI3-kinase activity,
which is also the case with ephrinB1-induced Rap1 activation. The
fact that PI3-kinase inhibitors reduce adhesion, but not Rap1
activation, would suggest that PI3-kinases support adhesion in a
pathway that is either downstream of Rap1 activation or independent of Rap1 activation (Figure 8).
In conclusion, the present studies show that activation of EphA4
and ephrinB1 on the platelet surface can support the binding of
␣IIb␤3 to immobilized fibrinogen and promotes aggregation in
response to biologically relevant platelet agonists. A sustained
activation of the integrin in the context of a fibrin- and fibrinogenembedded hemostatic plug would be expected to help to stabilize
the plug. Taken together, these results provide a mechanism by
which Eph/ephrin interactions can support the growth and stability
of the hemostatic plug and point to the direction in which the
necessary downstream effectors in platelets can be found.

Acknowledgments
We thank Gaston Vilaire, Joel Bennett, Hong Chen, Mark Kahn,
Peter O’Brien, and Jing Yang for many helpful discussions.

References
1. Prevost N, Woulfe D, Tanaka T, Brass LF. Interactions between Eph kinases and ephrins provide a
novel mechanism to support platelet aggregation
once cell-to-cell contact has occured. Proc Natl
Acad Sci U S A. 2002;99:9219-9224.
2. Wilkinson DG. Eph receptors and ephrins: regulators of guidance and assembly. Int Rev Cytol.
2000;196:177-244.
3. Adams RH, Klein R. Eph receptors and ephrin
ligands: essential mediators of vascular development. Trends Cardiovasc Med. 2000;10:183-188.
4. Cheng N, Brantley DM, Chen J. The ephrins and
Eph receptors in angiogenesis. Cytokine Growth
Factor Rev. 2002;13:75-85.
5. Schmucker D, Zipursky SL. Signaling downstream of Eph receptors and ephrin ligands. Cell.
2001;105:701-704.
6. Kullander K, Klein R. Mechanisms and function of
Eph and ephrin signaling. Nat Rev Mol Cell Biol.
2002;3:475-486.
7. Gale NW, Holland SJ, Valenzuela DM, et al. Eph

receptors and ligands comprise two major specificity subclasses and are reciprocally compartmentalized during embryogenesis. Neuron. 1996;
17:9-19.
8. Holland SJ, Gale NW, Mbamalu G, Vancopoulos
GD, Henkemeyer M, Pawson T. Bidirectional signaling through the the EPH-family receptor Nuk
and its transmembrane ligands. Nature. 1996;
383:722-725.
9. Mellitzer G, Xu Q, Wilkinson DG. Control of cell
behavior by signalling through Eph receptors and
ephrins. Curr Opin Neurobiol. 2000;10:400-408.
10. Prevost N, Woulfe D, Tognolini M, Brass LF. Contact dependent signaling during the late events of
platelet activation. J Thrombos Heamostas. 2003;
1:1613-1627.
11. Woulfe D, Prevost N, Jiang H, Tognolini M, Fortna
R, Brass LF. Eph receptor-ephrin interactions
contribute to the tyrosine phosphorylation of the
cytoplasmic domain of the ␤ subunit of ␣IIb␤3 during platelet aggregation [abstract]. Blood. 2002;
100:477a.

12. Prevost N, Fortna R, Tognolini M, Woulfe D, Wu
J, Brass LF. Contact-dependent signaling by Eph
kinases and ephrins promotes the late phases of
platelet activation, including clot retraction [abstract]. Blood. 2002;100:477a.
13. Bellavite P, Andrioli G, Guzzo P, et al. A colorimetric method for the measurement of platelet adhesion in microtiter plates. Anal Biochem. 1994;216:
444-450.
14. Himanen JP, Henkemeyer M, Nikolov DB. Crystal
structure of the ligand binding domain of the receptor tyrosine kinase EphB2. Nature. 1998;396:
486-491.
15. Reedquist KA, Ross E, Koop EA, et al. The small
GTPase, Rap1, mediates CD31-induced integrin
adhesion. J Cell Biol. 2000;148:1151-1158.
16. Katagiri K, Hattori M, Minato N, Irie S, Takatsu K,
Kinashi T. Rap1 is a potent activation signal for
leukocyte function-associated antigen 1 distinct
from protein kinase C and phosphatidylinositol3-OH kinase. Mol Cell Biol 2000;20:1956-1969.
17. Bertoni A, Tadokoro S, Eto K, et al. Relationships

BLOOD, 15 FEBRUARY 2004 䡠 VOLUME 103, NUMBER 4

between Rap1b, affinity modulation of integrin
␣IIb␤3, and the actin cytoskeleton. J Biol Chem.
2002;277:25715-25721.
18. Eto K, Murphy R, Kerrigan SW, et al. Megakaryocytes derived from embryonic stem cells implicate
CalDAG-GEFI in integrin signaling. Proc Natl
Acad Sci U S A. 2002;99:12819-12824.
19. De Bruyn KMT, Zwartkruis FTJ, De Rooij J, Akkerman J-WN, Bos JL. The small GTPase Rap1
is activated by turbulence and involved in integrin
␣IIb␤3-mediated cell adhesion in human
megakaryocytes. J Biol Chem. 2003;278:2241222417.
20. Sebzda E, Bracke M, Tugal T, Hogg N, Cantrell
DA. Rap1A positively regulates T cells via integrin
activation rather than inhibiting lymphocyte signaling. Nat Immunol. 2002;3:251-258.
21. Law DA, DeGuzman FR, Heiser P, Ministri-Madrid K, Killeen N, Phillips DR. Integrin cytoplasmic
tyrosine motif is required for outside-in ␣IIb␤3 signalling and platelet function. Nature. 1999;401:
808-811.

SIGNALING BY ephrinB1 AND Eph KINASES IN PLATELETS

1355

22. Phillips DR, Nannizzi-Alamio L, Prasad KSS.
Beta3 tyrosine phosphorylation in alphaIIbbeta3
(platelet membrane GP IIb-IIIa) outside-in integrin
signaling. Thromb Haemost. 2001;86:246-258.

27. Torres R, Firestein BL, Dong HL, et al. PDZ proteins bind, cluster, and synaptically colocalize
with Eph receptors and their ephrin ligands. Neuron. 1998;21:1453-1463.

23. Huynh-Do U, Stein E, Lane AA, Liu H, Cerretti
DP, Daniel TO. Surface densities of ephrin-B1
determine EphB1-coupled activation if cell attachment through alphavbeta3 and alpha5beta1 integrins. EMBO J. 1999;18:2165-2173.

28. Lin D, Gish GD, Songyang Z, Pawson T. The carboxyl terminus of B class ephrins constitutes a
PDZ binding motif. J Biol Chem. 1999;274:37263733.

24. Zou JX, Wang B, Kalo MS, Zisch AH, Pasquale
EB, Ruoslahti E. An Eph receptor regulates integrin activity through R-Ras. Proc Natl Acad Sci
U S A. 1999;96:13813-13818.
25. Becker E, Huynh-Do U, Holland S, Dawson T,
Daniel TO, Skolnik EY. Nck-interacting Ste20 kinase couples Eph receptors to c-Jun N-terminal
kinase and integrin activation. Mol Cell Biol.
2000;20:1537-1545.
26. Miao H, Burnett E, Kinch M, Simon E, Wang B.
Activation of EphA2 kinase suppresses integrin
function and causes FAK dephosphorylation. Nat
Cell Biol. 2000;2:62-69.

29. Lu Q, Sun EE, Klein RS, Flanagan JG. Ephrin-B
reverse signaling is mediated by a novel PDZRGS protein and selectively inhibits G proteincoupled chemoattraction. Cell. 2001;105:69-79.
30. Bruckner K, Pablo Labrador J, Scheiffele P, et al.
EphrinB ligands recruit GRIP family PDZ adaptor
proteins into raft membrane microdomains. Neuron. 1999;22:511-524.
31. Xu Z, Kwok-On L, Zhou H-M, Lin S-C, Ip NY. Ephrin-B1 reverse signaling activates JNK through a
novel mechanism that is independent of tyrosine
phosphorylation. J Biol Chem. 2003;278:2476724775.

